阿达木单抗治疗强直性脊柱炎的药物经济学文献研究现状 : = Pharmacoeconomic Literature Research Status of Adalimumab in the Treatment of Ankylosing Spondylitis
目的:归纳、总结阿达木单抗治疗强直性脊柱炎的相关药物经济学研究,探讨阿达木单抗治疗强直性脊柱炎的经济性。方法:计算机检索Medline、Embase、Web of Science、维普网、中国期刊全文数据库、万方数据,中文检索词包括"阿达木单抗""修美乐""强直性脊柱炎""成本效果""药物经济学评价""成本效用""成本效益"等;英文检索词包括"Adalimumab""Humira""Ankylosing spondylitis""AS""Cost effectiveness""Pharmaceutical economic evaluation""Pharmacoeconomics""Cost utility""Cost efficacy"等,语言限中、英文,检索时限均从2002年1月至2019年5月,收集阿达木单抗与传统治疗对比、阿达木单抗与其他生物制剂对比治疗强直性脊柱炎的相关药物经济学研究,包括成本分析、成本-效果分析、成本-效用分析、成本-效益分析。对纳入研究的发表国家、研究方法、经济学评价结果等进行归纳、总结。结果:共纳入6篇文献,涉及6项研究,文献主要分布在英国、加拿大、荷兰,最常用的研究方法是Markov模型。阿达木单抗治疗强直性脊柱炎对比传统治疗在英国的增量-成本效果比为19 275～26 556英镑,具有成本-效果优势。阿达木单抗与其他生物制剂的对比结果在不同研究中存在差异。结论:在英国,阿达木单抗治疗强直性脊柱炎对比传统治疗具有经济学优势,但国内相关研究尚缺乏,亟待开展相关研究。.
OBJECTIVE: To collect and summarize the pharmacoeconomic studies of adalimumab in the treatment of ankylosing spondylitis,and to explore the economics of adamumab in the treatment of ankylosing spondylitis. METHODS:Retrieved from Medline, Embase, Web of Science, VIP, CJFD and Wanfang databases, Chinese search terms included"adalimumab""humira""ankylosing spondylitis""cost effectiveness""pharmacoeconomic evaluation""cost utility""cost efficacy" etc. English search terms included "Adalimumab""Humira""Ankylosing spondylitis""AS""Cost effectiveness""Pharmaceutical economic evaluation""Pharmacoeconomics""Cost utility""Cost efficacy",etc. The language is Chinese or English.The retrieval time was from January 2002 to May 2019. The pharmacoeconomic studies of adalimumab vs. traditional treatment,adalimumab vs. other biological agents in the treatment of ankylosing spondylitis were collected,including cost analysis,cost-effectiveness analysis,cost-effectiveness analysis and cost-benefit analysis.The included studies were summarized in terms of countires,research method and economic evluation results. RESULTS:Six papers were included,involving six studies. The literature was mainly distributed in the UK,Canada and the Netherlands. The Markov model was most commonly used.The incremental cost-effectiveness ratio of adalimumab in the treatment of ankylosing spondylitis was ￡19 275-26 556 in UK,and adalimumab had cost-effectiveness advantage. The cost-effectiveness advantage between adalimumab and other biological agents was varied in different studies. CONCLUSIONS:Compared with conventional therapy,adalimumabhas economic advantages in the treatment of ankylosing spondylitis in UK. But there was lack of relevant research in China,which needs to be carried out urgently..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-09-15 2019 |
|---|---|
| Erschienen: |
2019-09-15 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Zhong guo yao fang - (2019), 17 vom: 15. Sept., Seite 2384-2387 Original Letters: Enthalten in 中国药房 (DE-600)2989708-7 (DE-600)2989708-7 重庆市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Pharmacoeconomic Literature Research Status of Adalimumab in the Treatment of Ankylosing Spondylitis |
|---|
| Beteiligte Personen: |
吴逢波 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:WU Fengbo;WU Bin;SUN Wenxu;XU Ting;Dept.of Clinical Pharmacy,West China Hospital,Sichuan University |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ63927840X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ63927840X | ||
| 003 | DE-627 | ||
| 005 | 20230120193721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230103s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ63927840X | ||
| 035 | |a (SBB-XA)CAJ_ZGYA201917016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R593.23 |2 clc | ||
| 084 | |a R956 |2 clc | ||
| 100 | 0 | |a 吴逢波 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 阿达木单抗治疗强直性脊柱炎的药物经济学文献研究现状 |b = Pharmacoeconomic Literature Research Status of Adalimumab in the Treatment of Ankylosing Spondylitis |
| 246 | 3 | 1 | |a Pharmacoeconomic Literature Research Status of Adalimumab in the Treatment of Ankylosing Spondylitis |
| 264 | 1 | |c 2019-09-15 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:WU Fengbo;WU Bin;SUN Wenxu;XU Ting;Dept.of Clinical Pharmacy,West China Hospital,Sichuan University | ||
| 520 | |a 目的:归纳、总结阿达木单抗治疗强直性脊柱炎的相关药物经济学研究,探讨阿达木单抗治疗强直性脊柱炎的经济性。方法:计算机检索Medline、Embase、Web of Science、维普网、中国期刊全文数据库、万方数据,中文检索词包括"阿达木单抗""修美乐""强直性脊柱炎""成本效果""药物经济学评价""成本效用""成本效益"等;英文检索词包括"Adalimumab""Humira""Ankylosing spondylitis""AS""Cost effectiveness""Pharmaceutical economic evaluation""Pharmacoeconomics""Cost utility""Cost efficacy"等,语言限中、英文,检索时限均从2002年1月至2019年5月,收集阿达木单抗与传统治疗对比、阿达木单抗与其他生物制剂对比治疗强直性脊柱炎的相关药物经济学研究,包括成本分析、成本-效果分析、成本-效用分析、成本-效益分析。对纳入研究的发表国家、研究方法、经济学评价结果等进行归纳、总结。结果:共纳入6篇文献,涉及6项研究,文献主要分布在英国、加拿大、荷兰,最常用的研究方法是Markov模型。阿达木单抗治疗强直性脊柱炎对比传统治疗在英国的增量-成本效果比为19 275～26 556英镑,具有成本-效果优势。阿达木单抗与其他生物制剂的对比结果在不同研究中存在差异。结论:在英国,阿达木单抗治疗强直性脊柱炎对比传统治疗具有经济学优势,但国内相关研究尚缺乏,亟待开展相关研究。 | ||
| 520 | |a OBJECTIVE: To collect and summarize the pharmacoeconomic studies of adalimumab in the treatment of ankylosing spondylitis,and to explore the economics of adamumab in the treatment of ankylosing spondylitis. METHODS:Retrieved from Medline, Embase, Web of Science, VIP, CJFD and Wanfang databases, Chinese search terms included"adalimumab""humira""ankylosing spondylitis""cost effectiveness""pharmacoeconomic evaluation""cost utility""cost efficacy" etc. English search terms included "Adalimumab""Humira""Ankylosing spondylitis""AS""Cost effectiveness""Pharmaceutical economic evaluation""Pharmacoeconomics""Cost utility""Cost efficacy",etc. The language is Chinese or English.The retrieval time was from January 2002 to May 2019. The pharmacoeconomic studies of adalimumab vs. traditional treatment,adalimumab vs. other biological agents in the treatment of ankylosing spondylitis were collected,including cost analysis,cost-effectiveness analysis,cost-effectiveness analysis and cost-benefit analysis.The included studies were summarized in terms of countires,research method and economic evluation results. RESULTS:Six papers were included,involving six studies. The literature was mainly distributed in the UK,Canada and the Netherlands. The Markov model was most commonly used.The incremental cost-effectiveness ratio of adalimumab in the treatment of ankylosing spondylitis was ￡19 275-26 556 in UK,and adalimumab had cost-effectiveness advantage. The cost-effectiveness advantage between adalimumab and other biological agents was varied in different studies. CONCLUSIONS:Compared with conventional therapy,adalimumabhas economic advantages in the treatment of ankylosing spondylitis in UK. But there was lack of relevant research in China,which needs to be carried out urgently. | ||
| 610 | 2 | 4 | |a 四川大学华西医院临床药学部 |
| 650 | 4 | |a 全身性疾病、地方病学 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a 药事组织 | |
| 650 | 4 | |a 药学 | |
| 650 | 4 | |a Endocrine and Systemic Disease | |
| 650 | 4 | |a Pharmaceutics | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 阿达木单抗 | |
| 650 | 4 | |a 强直性脊柱炎 | |
| 650 | 4 | |a 药物经济学 | |
| 650 | 4 | |a 成本-效果 | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a Ankylosing spondylitis | |
| 650 | 4 | |a Pharmacoeconomics | |
| 650 | 4 | |a Cost-effectiveness | |
| 700 | 0 | |a 吴斌 |4 oth | |
| 700 | 0 | |a 孙闻续 |4 oth | |
| 700 | 0 | |a 徐珽 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Zhong guo yao fang |d Zhong qing shi, 1990 |g (2019), 17 vom: 15. Sept., Seite 2384-2387 |h Online-Ressource |w (DE-627)CAJ247051845 |w (DE-600)2989708-7 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:17 |g day:15 |g month:09 |g pages:2384-2387 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZGYA201917016 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZGYA201917016 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 中国药房 |d 重庆市 |h Online-Ressource |w (DE-627)CAJ247051845 |w (DE-600)2989708-7 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 17 |b 15 |c 09 |h 2384-2387 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 17 |b 15 |c 09 |h 2384-2387 | ||
| 980 | |2 11 |1 01 |x 0001 |b 658783262 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 03-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZGYA201917016 | ||